Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest genotype Stories

2012-04-18 22:21:49

BARCELONA, Spain, April 19, 2012 /PRNewswire/ -- Further data shows PegIFN-lambda's comparable efficacy but better safety profile than PegIFN-alpha New data presented at the International Liver Congress(TM) 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The much anticipated data from a number of clinical trials[1],[2],[3],[4],[5],[6] confirm that combinations of antivirals offer the hope of...

2012-04-18 22:21:37

BARCELONA, Spain and RIDGEFIELD, Conn., April 19, 2012 /PRNewswire/ -- New data from a descriptive sub-analysis of patients with compensated liver cirrhosis show that up to 43 percent of genotype-1a (GT1a) and up to 71 percent of GT1b hepatitis C virus (HCV) patients achieved sustained viral response (SVR12). SVR12 has been highly correlated with SVR24, which is a recognized indicator of viral cure.( )This descriptive sub-analysis from SOUND-C2, a Phase 2b study evaluating interferon-free...

2012-04-18 22:21:33

BARCELONA, Spain and RIDGEFIELD, Conn., April 19, 2012 /PRNewswire/ -- New data from a pre-specified interim analysis of the Phase 2b SOUND-C2 study show that 68 percent of genotype-1 (GT1) hepatitis C virus (HCV) patients achieved sustained viral response 12 weeks after the end of treatment (SVR12) with Boehringer Ingelheim's investigational direct-acting antiviral compounds - the protease inhibitor BI 201335 and polymerase inhibitor BI 207127 - plus ribavirin (RBV), without interferon....

2012-04-18 06:27:44

BARCELONA, Spain, April 18, 2012 /PRNewswire/ -- - Retrospective sub-analyses from ADVANCE, ILLUMINATE and REALIZE Phase 3 studies will be presented at European Association for the Study of the Liver (EASL) 2012 - Janssen Pharmaceutica NV (Janssen) will present new data for INCIVO (telaprevir) from Phase 3 retrospective sub-analyses at the 47th annual meeting of the European Association for the Study of the Liver (EASL) in Barcelona. The data shows that similar...

2012-04-18 02:28:53

STOCKHOLM, April 18, 2012 /PRNewswire/ -- - Expanded clinical study program evaluating a combination of TMC435 and daclatasvir (BMS-790052) - TMC435 and BMS-986094 (formerly INX-189), two direct-acting antivirals in combination, will be evaluated in clinical trial Medivir AB (OMX:MVIR), the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, announces that...

2012-04-04 06:27:17

WATERTOWN, Mass., April. 4, 2012 /PRNewswire/ --Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that key data from two of its hepatitis C (HCV) programs will be presented at the International Liver Congress(TM) 2012 (ILC2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain. Oral...

2012-04-04 06:26:54

BEERSE, Belgium, April 4, 2012 /PRNewswire/ -- Not Intended for US Journalists - Analysis to be presented at European Association for the Study of the Liver (EASL) 2012 shows clinical and cost-effectiveness regardless of IL28B subtype - Janssen Pharmaceutica NV (Janssen) will present a cost-effectiveness analysis for INCIVO(telaprevir) at the 47th annual meeting of the European Association for the Study of the Liver (EASL) in Barcelona. The analysis...

2012-04-04 06:26:49

ABBOTT PARK Ill., April 4, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C (HCV) at the International Liver Congress(TM) 2012 (ILC 2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain. Abstracts for the meeting were published online today. In the study known as "Co-Pilot," different doses of ABT-450/r, plus...

2012-03-26 10:24:00

Province to reimburse new chronic hepatitis C treatment MONTREAL, March 26, 2012 /PRNewswire/ - BC PharmaCare recently announced the reimbursement of VICTRELIS(TM) (boceprevir) for eligible British Columbians living with chronic hepatitis C. Boceprevir is a first-in-class oral hepatitis C virus (HCV) protease inhibitor for the treatment of chronic hepatitis C genotype 1 infection. It is to be used in combination with peginterferon alpha and ribavirin (peg/riba) in adult patients...

Australia Suffers Under New Strain Of Whooping Cough
2012-03-22 05:50:54

A new strain of whooping cough has been eluding vaccines and causing the number of whooping cough cases to rise sharply in Australia. Scientists from the University of New South Wales led the research and discovered a new genotype (called prn2-ptxP3) of B. pertussis, the whooping cough bacteria. This new strain has been resistant to the current acellular vaccine (ACV) given to treat whooping cough. As such, cases of the potentially fatal respiratory illness are on the rise. These...